BMS Buying Padlock For Up To $600 Million
This article was originally published in Start Up
Two years, $18 million and a big pharma buyout for up to $600 million? That's a great return for investors in Padlock Therapeutics, a biotech firm that raised a single venture capital round in late 2014 to develop novel treatments for autoimmune diseases before Bristol-Myers Squibb agreed to buy the company.
Register for our free email digests: